NeuroSense is collaborating with PhaseV to gain insights into how to optimize the protocol for a planned Phase 3 trial of ...

An old adage says, “Do something today that your future self will thank you for.” Well, I’m in that future now, so today, I’m ...

A Phase 1/2 clinical trial of BIIB105 showed a lack of benefit, leading Biogen and Ionis to terminate development of the ...

The DNL343 arm of the HEALEY ALS platform trial, which is concurrently testing multiple therapies for ALS, has completed ...

Broken String Biosciences and Francis Crick Institute scientists are teaming up to better understand how DNA damage ...

An assessment called delta-FS may be an easy-to-obtain tool to monitor disease severity and assess prognosis in ALS, ...

Over the next eight years, the funds will be invested to fuel scientific breakthroughs and drive the development of ...

Epigenetics, or chemical changes in DNA that alter gene activity, may be key to predicting ALS disease progression, a study ...

A University of Illinois PhD student in bioengineering won a $20,000 Innovation Award for her work on next-generation ...

Researcher Eva Feldman, MD, PhD has studied how occupational exposures are linked to the development and progression of ALS.

PrimeC has been shown, per PARADIGM trial data, to significantly slow ALS in patients who are newly diagnosed or at high risk ...

Columnist Juliet Taylor shares an ALS Awareness Month reflection on love, loss, and hope for a better future in life with ALS ...